Targeting Dendritic Cells as a Good Alternative to Combat Leishmania spp. by Rafael Freitas-Silva et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OPINION ARTICLE
published: 26 November 2014
doi: 10.3389/fimmu.2014.00604
Targeting dendritic cells as a good alternative to combat
Leishmania spp.
Rafael de Freitas e Silva1,2*, Maria Carolina Accioly Brelaz de Castro2, Antônio Mauro Rezende3 and
Valéria RêgoAlves Pereira2
1 Department of Natural Sciences, University of Pernambuco, Garanhuns, Brazil
2 Department of Immunology, Aggeu Magalhães Research Center, Oswaldo Cruz Foundation, Recife, Brazil
3 Department of Microbiology, Aggeu Magalhães Research Center, Oswaldo Cruz Foundation, Recife, Brazil
*Correspondence: rafael.silva@upe.br
Edited by:
Lee MarkWetzler, Boston University School of Medicine, USA
Reviewed by:
Paul Cos, Antwerp University, Belgium
Keywords: dendritic cells, vaccine, neglected diseases, leishmaniasis
LEISHMANIASIS: GLOBAL BURDEN,
CLINICAL FORMS, AND CURRENT
STRATEGIES OF CONTROL
Leishmaniasis is an important group of
neglected diseases caused by more than
20 spp. of protozoan from the genus Leish-
mania. It is transmitted by sandfly bite
(1), and impacts populations by inducing
disfiguration, loss of productivity, and a
burden estimated at 2,357.000 disability-
adjusted life years (DALY) (2). Ninety-
eight countries have reported cases of leish-
maniasis, and over 350 million people
are living at risk, with 0.2–0.4 and 0.7–
1.2 million cases of VL and CL annu-
ally, respectively (3). Three main clinical
forms are known: visceral (VL, more lethal,
e.g., L. donovani and L. infantum), cuta-
neous (CL, more common, e.g., L. major),
and mucocutaneous (MCL). Strategies to
limit these diseases are controlling the vec-
tors and chemotherapy of affected indi-
viduals, but these approaches have a high
cost and led to resistant parasites and vec-
tors (4). Thus, there is an urgent need
of vaccines and more effective therapies
for leishmaniasis, otherwise the number
of cases and resistant strains will prob-
ably continue to rise. Since they have a
key capacity to initiate and maintain an
immune response, dendritic cells (DCs)
have been seen as an important target
for the control of different diseases, such
as leishmaniasis. Thus, in this article we
present the principal strategies to efficiently
induce activation of DCs in the context of
leishmaniasis.
DENDRITIC CELLS AS THE MAIN
TARGET OF VACCINES AGAINST
LEISHMANIA
The major task for a vaccine is to correctly
induce the immune system to develop a
protective response against one specific
pathogen. In the case of leishmaniasis, this
protection comes from Th1 CD4+ T cells
producing IFN-γ, TNF, and IL-12, which
have been associated with disease con-
trol, macrophage activation, and elimina-
tion of parasites (5). However, to initi-
ate this response, antigen presenting cells
(APCs), present in different tissues of the
body, must be activated to induce a proper
response to eliminate or control the para-
site. DCs are highly specialized APCs of the
immune system capable of priming naïve
T cells, and mounting a T-cell response
upon pathogen entry in the body. Dis-
tinct subsets of DCs are associated with
lineages and receptor expression patterns
(6), and they develop from hematopoietic
stem cells stimulated with fms-like tyrosine
kinase 3 ligand (Flt3L) or with granulo-
cyte/macrophage colony-stimulating fac-
tor (GM-CSF) (7). The majority of DCs
develop from myeloid precursors, whereas
plasmacytoid DC (pDC) develops from
lymphoid precursors and shares many fea-
tures with B cells (8). To aid in their
function, DCs express different toll-like
receptors (TLR), which bind to common
molecules associated with pathogens, and
have been target for the development of
new vaccine adjuvants. DCs express a
large variety of receptors involved with
uptake of molecules and pathogens, such as
DC-SIGN (CD209) and DEC205 (CD205)
(9). Immature DCs have a high endo-
cytic capacity, which leads to pathogen or
pathogen’s antigens degradation, process-
ing, and finally loading of major histo-
compatibility complex (MHC) molecules.
Later, mature DCs lose their high capac-
ity of endocytosis, and change efforts to
up-regulate the expression of several recep-
tors for cytokines, MHC, adhesion, and
co-stimulatory molecules, such as CD80,
CD86, and CD40. It is estimated that
each mature DC expresses around 106–107
MHC Class II and 105 MHC Class I mol-
ecules, and “fix” a repertoire of peptides
bounded onto MHC Class II to present to
T cells (10). Eventually, DCs acquire capac-
ity to activate a specific T-cell response
against the pathogen that induced its acti-
vation (11). The last years were marked
by an increase in the knowledge on the
role and function of DCs in the immune
system, and thus, the emergence of poten-
tial applications based on its manipula-
tion. Starting on the field of cancer, which
finally led to the US FDA approval of a
DC-based vaccine against prostate cancer
(Sipuleucel-T, Provenge®) (12), applica-
tions were quickly transferred to the field of
infectious diseases with very encouraging
clinical results against HIV (13). Although
prospective results for infectious diseases
were achieved, there is no DC vaccine or
therapy for any infectious diseases that are
currently available or in the pipeline (14,
15). Most of the results were gathered by
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ex vivo manipulation of DCs, and in vitro
assays by loading it with desired antigens.
EX VIVO ASSAYS WITH DCs
Different researches have shown interest-
ing results with murine models vaccinated
with DCs ex vivo loaded with leishmania
lysate antigen (14, 16). These results were
encouraging since they showed that ani-
mals presented low levels of parasite bur-
den and high levels of protective cytokines
from the Th1 profile after vaccination. DCs
engineered to overexpress IL-12 were suc-
cessfully used for both vaccination and
immunotherapy of murine models with
infections already established (17). Inter-
estingly, it was also reported that differ-
ent subsets of DCs may induce different
responses upon activation. Vaccination of
BALB/c mice with pDCs pulsed with L.
major complete antigen showed that they
were protected against subsequent infec-
tion (18). In parallel, the use of DCs
pulsed with L. donovani-soluble antigen
combined with chemotherapy with pen-
tavalent antimonials was able to eradicate
parasites from infected mice (19). Curi-
ously, regarding viability of DCs present
in the vaccine, Schnitzer et al. (20) have
reported that fragments of DCs or exo-
somes derived from DCs that had been
previously exposed to parasite lysate of L.
major, conferred protection in susceptible
mice. Although modulation of DCs activity
is highly dependent on the specie of Leish-
mania causing the infection, some of these
studies were performed using L. major that
is responsible for cases of CL. Thereby,
there is an outstanding importance of stud-
ies dedicated to evaluate the action of
molecular defined antigens of Leishma-
nia spp. in the activity of DCs as a tar-
get for vaccines. Furthermore, many anti-
gens from the Leishmania spp. proteome
have unknown function and could be key-
molecules to induce protective immunity.
The importance of using defined antigens
is so expressive that DCs pulsed with pep-
tide (154–169aa) from gp63 induced a Th1
protection in BALB/c mice infected with
L. major, while stimulation with a second
peptide (467–482aa) resulted in a Th2 shift
and disease exacerbation (21). In this sense,
computational immunology has been con-
stantly increasing its value, and now diverse
in silico approaches are available for identi-
fication of potential epitopes and antigens
for vaccines, since experimental methods
are difficult and time-consuming (22). In
addition, the DNA sequencing techniques
are getting cheaper, therefore, many para-
site genome strains can be sequenced and
their predicted proteomes can be assessed
regarding their variability, an important
feature for antigen candidates for vac-
cine development. Thus, sequence- and
structure-based methods investigating the
binding affinity of peptides to the MHC
molecules Class I and II, and other para-
meters such as sequence diversity may aid
in the search of new antigens (23). Tak-
ing advantages of these methods, Agallou
et al. (24) have recently reported the con-
struction of a multi-epitope peptide vac-
cine against leishmaniasis by analyzing four
known proteins from L. infantum. In this
last study, some of the proteins (histone H1
and KMP-11) have been previously tested
in DCs vaccines against L. infantum (25,
26). Different studies for vaccines against
Leishmania spp. have used defined mole-
cules for classical immunization, without
considering aspects of DCs activation, and
maintenance of a Th1 response by mem-
ory cells. DCs have been implicated with
the induction of a Th1 immune response
through the production of IL-12, as seen in
C57BL/6 and C3H resistant mice strains.
On the other hand, BALB/c susceptible
mice are more prone to produce a Th2
immune response with the presence of IL-
4, IL-5, and IL-13; IL-4−/− BALB/c mice
were capable to partially control the infec-
tion with some strains of L. major (27).
It has been shown that IL-4 during the
early phase of DC activation induces a
potent Th1 response induced by IL-12 (28);
and in the context of vaccination with
DCs, it was reported that IL-4 might be
an important adjuvant, since IL-4Rα sig-
naling is key to promote a Th1 immune
response (14). Studies have enrolled IL-10
with disease progression by means of sup-
pression of the anti-leishmanial immune
response in humans and mice (29–31).
Recently, Schwarz et al. (16) have shown
that T cell are the main source of IL-10
in early infection, however, BALB/c mice
vaccinated with fragmented DCs that had
been pulsed with L. major lysate and CpG
oligodeoxynucleotides (CpG-ODN) were
able to suppress IL-10 favoring the con-
trol of infection. One of the main concerns
in the vaccine development is the use of
adjuvants, in this regard, DC approaches
in leishmaniasis studies have used, mainly,
CpG-ODN, which is a TLR9 ligand (32).
The effect of CpG-ODN is to induce
DC activation and maturation, enhanc-
ing humoral responses, with Th1 indicator
IgG2a antibodies, and activity of cytotoxic
T lymphocytes (CTL) (33, 34). It has been
shown that CpG-ODN induce the produc-
tion of CXCL10, a chemokine with anti-
leishmanial properties, regulation of para-
sitic load, and CD4+CD25+ regulatory T
(Treg) cells in mice infected with L. dono-
vani (35, 36). Some issues may concern this
approach of ex vivo activation, such as the
type of antigen that is used, the method
itself, which is time-consuming and labor,
and also the high risk of infection.
OVERALL ADVANTAGES OF IN VIVO
ACTIVATION OF DCs
Toward a more rational and feasible DC-
based vaccine against different pathogens,
groups of research have endeavored to
in vivo manipulate DCs, and thus, trying
to understand the ways of induction a spe-
cific T cell response. In a very interesting
work, Bonifaz et al. (37) have demonstrated
that it is possible to manipulate DCs in vivo
by directing antigen-conjugated antibod-
ies against uptake receptors (DEC205).
Other works followed the same strategy
and achieved promising results for different
pathogens, such as HIV, and also induc-
tion of immunity in distinct sites that are
challenges for classical route immuniza-
tion, such as mucosal sites (38, 39). For
L. major, it was shown that in vivo tar-
geting of DEC205 receptor of DCs with
different antigen (LACK, LeIF, LmSTI1a)-
conjugated antibodies can elicit a protec-
tive immune response with INF-γ and
TNF-α in different mice strains (40).
Therefore, based on these results collected
during the last years, other uptake recep-
tors could be a target to proper induce DCs
maturation and activation. Nevertheless, as
well as for other approaches, for a vaccine
against Leishmania is not different, as there
is a big gap in translating the research from
murine models to humans due to envi-
ronmental and genetic differences (41).
Since murine models are difficult and do
not always reproduce Leishmania infec-
tion, it might be interesting to test some of
these approaches with cells from individ-
uals affected or living in endemic regions,
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like recently described for other types of
vaccine (42). Another ongoing challenge
to be considered is the number of DCs
present in vivo. DCs in vivo are rarer than
other leukocyte populations. To overcome
this issue, it has been shown that using
Flt3L in vivo through gene transfection,one
can enhance the number of DCs in vivo
(43). In this context, it is worth mention-
ing the importance of works designed for
VL, due to its high mortality level. However,
in terms of number of cases and morbid-
ity, CL and MCL are much more expressive
than VL, especially in developing nations,
such as Brazil.
CONCLUSION AND PERSPECTIVES
The results of DCs-based vaccines against
leishmaniasis are very encouraging;
demonstrating that either ex vivo or
in vivo target of DCs can elicit an effective
immune response to combat Leishma-
nia spp. However, a number of biological
and methodological challenges should be
overcome prior to the development of a
DCs-based vaccine. It is possible that mov-
ing researches forward to animal, and then,
clinical studies will better point out if the
target of DCs is safe and effective for an
anti-Leishmania spp. vaccine.
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